A Look At Arcadis (ENXTAM:ARCAD) Valuation After Recent Share Price Weakness

A Look At Arcadis (ENXTAM:ARCAD) Valuation After Recent Share Price Weakness

Simply Wall St

Tue, February 24, 2026 at 11:11 AM GMT+9 3 min read

In this article:

ARCAD.AS

-5.15%

Find your next quality investment with Simply Wall St’s easy and powerful screener, trusted by over 7 million individual investors worldwide.

Short term share performance and recent context

Arcadis (ENXTAM:ARCAD) has drawn investor attention after a period of weaker share performance, with the stock showing negative returns over the past week, month, past 3 months and 1 year.

At a last close of €28.00, Arcadis carries a value score of 5, with reported annual revenue of €4,875.0m and net income of €208.0m, alongside positive annual net income growth.

See our latest analysis for Arcadis.

The recent 25.5% 1 month share price decline and 42.2% 1 year total shareholder return loss suggest momentum is fading, which may indicate investors are reassessing Arcadis’s growth prospects and risk profile relative to its current €28.0 share price.

If Arcadis’s recent weakness has you reassessing your watchlist, this could be a good moment to widen your scope and check out 101 top founder-led companies as potential long term compounders.

With the share price under pressure and Arcadis trading below analyst price targets and some intrinsic value estimates, you now have to ask whether this weakness is a genuine opening or whether the market is already discounting future growth.

Most Popular Narrative: 46% Undervalued

With Arcadis last closing at €28.00 against a most-followed fair value estimate of €51.89, the current share price sits well below that narrative view. This view is built on explicit assumptions about revenue, margins and required return using a 6.26% discount rate.

Robust investment in digitalization, including proprietary platforms (EDA, EDA Lite), AI, and enterprise asset management, is enhancing Arcadis’ capabilities in smart infrastructure, enabling cross-selling, greater recurring revenues, and supporting structural margin improvement.

Read the complete narrative.

Want to see what kind of earnings path and margin reset would have to line up with that view, and how revenue contraction still fits into a higher fair value? The full narrative spells out the growth profile, profitability shift and valuation multiple that need to hold for €51.89 to make sense.

Result: Fair Value of €51.89 (UNDERVALUED)

Have a read of the narrative in full and understand what’s behind the forecasts.

However, this depends on Arcadis turning heavy digital and workforce spending into higher margins while avoiding further project delays or integration issues that could keep earnings under pressure.

Find out about the key risks to this Arcadis narrative.

Story Continues  

Next Steps

If this mix of share price weakness and an undervaluation narrative leaves you on the fence, it may be worth looking through the full data now and weighing both sides of the story for yourself, including the 3 key rewards and 2 important warning signs that sit behind it.

Looking for more investment ideas?

If Arcadis is on your radar, do not stop there; broaden your opportunity set with a few focused stock ideas that match different investing priorities.

Target dependable income by reviewing 444 dividend fortresses, so you do not miss companies that currently combine higher yields with an emphasis on stability.
Hunt for potential bargains using 230 high quality undervalued stocks, especially if you want stocks where market expectations look modest relative to underlying fundamentals.
Prioritise resilience with 324 resilient stocks with low risk scores, a list built for investors who would rather miss a hot trade than overlook sturdier balance sheets and risk profiles.

_ This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned._

Companies discussed in this article include ARCAD.AS.

Have feedback on this article? Concerned about the content? Get in touch with us directly._ Alternatively, email editorial-team@simplywallst.com_

Terms and Privacy Policy

Privacy Dashboard

More Info

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
0/400
No comments
  • Pin